Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sotalol: a new class III antiarrhythmic agent

L A Zanetti1

  • 1Catherine McAuley Health Systems, St. Joseph Mercy Hospital, Ann Arbor, MI 48106.

Clinical Pharmacy
|December 1, 1993
PubMed
Summary

Sotalol hydrochloride is a Class III antiarrhythmic and beta-blocker effective for ventricular and supraventricular arrhythmias. Review covers its chemistry, pharmacology, efficacy, and dosage, with adverse effects noted.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potentiation of warfarin's hypoprothrombinemic effect with miconazole vaginal suppositories.

Pharmacotherapy·2000
Same author

Role of beta-adrenergic-receptor antagonists with intrinsic sympathomimetic activity.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1995
Same author

Increasing pharmacist involvement in cardiopulmonary resuscitation attempts.

American journal of hospital pharmacy·1993
Same author

Visual compatibility of diltiazem with commonly used injectable drugs during simulated Y-site administration.

American journal of hospital pharmacy·1992

Area of Science:

  • Pharmacology
  • Clinical Therapeutics
  • Cardiovascular Medicine

Background:

  • Sotalol hydrochloride is a Class III antiarrhythmic agent with nonselective beta-blocking activity.
  • It prolongs cardiac action potential and refractoriness, impacting electrophysiological properties.

Purpose of the Study:

  • To review the chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage of sotalol hydrochloride.
  • To assess its utility in managing life-threatening arrhythmias.

Main Methods:

  • Comprehensive literature review of sotalol hydrochloride.
  • Analysis of pharmacokinetic data, clinical trial results, and adverse event reports.

Main Results:

  • Sotalol is orally absorbed, eliminated renally with a 12-hour half-life, and effective for ventricular arrhythmias (VT, VF, PVCs) and supraventricular arrhythmias.
  • Common adverse effects include fatigue, GI issues, and cardiovascular effects like bradycardia and AV block; 6-18% require discontinuation.

Conclusions:

  • Sotalol hydrochloride is valuable for intractable ventricular arrhythmias and supraventricular arrhythmias unresponsive to other treatments.
  • Appropriate dosing and monitoring are crucial due to potential adverse effects.

Related Experiment Videos